Lunesta
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
FDA has required the manufacturer of sleep drug eszopiclone (Lunesta) to lower the starting dose from 2 mg to 1 mg.
Patients were randomized to pharmacotherapy with 3 mg Lunesta or to a standardized meditation-based intervention (MBSR) for the 5…
Eszopiclone (Lunesta), manufactured by Sepracor Inc., is a new nonbenzodiazepine hypnotic developed for the treatment of insomnia…
INTRODUCTION Insomnia is a condition that affects nearly everyone at some point in life. Up to 40% of American adults have…